Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial

    - Conference Call on September 13 to Discuss Phase 1 Trial and Other
    Major Milestones -

    SAN DIEGO, CA, Sept. 10 /CNW/ - Nventa Biopharmaceuticals Corporation
(TSX:NVN) today announced the initiation of its Phase 1 clinical trial to
assess the safety and tolerability of new HspE7 (HspE7 dosed with an adjuvant)
in 24 patients with cervical intraepithelial neoplasia (CIN). In addition to
the key objective of assessing safety and tolerability, a secondary objective
of the study is to assess T-cell and B-cell specific human papillomavirus
(HPV)-E7 immune responses.
    "Advancing our lead therapeutic vaccine program back into human clinical
trials represents a major milestone for Nventa," said Peter Emtage, Ph.D.,
Vice President, Research and Development at Nventa. "Based on the impressive
preclinical data collected to date using HspE7 combined with multiple
adjuvants, we expect this trial to produce invaluable safety, tolerability and
immunological biomarker data of new HspE7 for use in designing future efficacy
    Following successful completion of this Phase 1 trial, the Company
anticipates launching a Phase 2 clinical trial with new HspE7 in patients with
high-grade cervical intraepithelial neoplasia (CIN 2/3). The Company is also
in discussions with clinical investigators regarding the design and
implementation of a second Phase 2 trial with new HspE7 in patients that are
HIV-positive with low-grade CIN.

    HspE7 + Adjuvant Phase 1 Trial Design:
    The trial is a multicenter, nonrandomized, open-label Phase 1 safety
study. The safety and tolerability of HspE7 and adjuvant administered
concomitantly will be assessed following subcutaneous doses of HspE7 (500
mcg/dose) plus graduated doses of adjuvant in patients with CIN. An additional
cohort administered a higher dose of HspE7 may be implemented if deemed
appropriate by data from previous cohorts. Patients will be immunized every 28
days for a period of 8 weeks (3 administrations). Post-treatment evaluations
will begin four weeks after the last of the three injections. Patients
enrolled with high-grade CIN (CIN 2/3) disease will be eligible to undergo
clinically appropriate treatment of the cervix at the twelfth week of the
    Nventa will also collect immunological data from these patients that may
provide an early indication of potential efficacy of the compound. To
determine if HspE7 plus adjuvant elicit T-cell and B-cell specific HPV-E7
immune responses, all patients will be typed for class I and II human
leukocyte antigen (HLA) subtypes, and will be evaluated for cytokine
responses, anti-HspE7 antibodies and cellular (T-cell) immunology.

    Conference Call:
    Nventa will hold a conference call on Thursday, September, 13, 2007, at
9:00 am Eastern Time (6:00 am Pacific Time) to allow securities analysts and
shareholders the opportunity to hear Management discuss an update on the
progress with HspE7 and other important milestones.

      Live Participant Dial In Numbers:
      If you are in the U.S. or Canada call (Toll Free): 877 407-8031. If you
      are International call: 201 689-8031.

      Replay of Audio Portion:
      A replay of this call will be available at 12:00 noon Eastern Time from
      September 13 through 11:59 pm Eastern Time on September 20, 2007. The
      playback number (Toll Free): 877-660-6853 (North America) or 201 612-
      7415 (International), Account Number: 286; Conference Identification
      Number: 254756 (both required for playback).

      Nventa will also webcast its investor call on Thursday, September 13,
      2007, at 9:00 am Eastern Time (6:00 am Pacific Time). The call is being
      webcast by Vcall and can be accessed through Nventa's website at
      www.nventacorp.com. Investors can also access the webcast at
      www.InvestorCalendar.com. The webcast will be available for replay
      through October 13, 2007.

    About HspE7, Lead Product Candidate:
    HspE7 is a novel therapeutic vaccine candidate for the treatment of
diseases caused by the human papillomavirus (HPV), one of the most common
sexually transmitted diseases in the world. HspE7 is derived from Nventa's
proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology
to covalently fuse stress proteins to target antigens, thereby stimulating
cellular immune system responses. Heat shock proteins (Hsps), also known as
stress proteins, are naturally present in the human body and play important
roles in the immune system, including transporting substances within cells and
activating cells of the immune system. Nventa is pursuing clinical development
of HspE7 in combination with an adjuvant.

    About Nventa Corporation:
    Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock
Exchange under the symbol NVN. For more information about Nventa, please visit

    This press release contains statements which, to the extent that they are
not recitations of historical fact may constitute forward-looking information
under applicable Canadian securities legislation or forward-looking statements
within the meaning of the United States Private Securities Litigation Reform
Act of 1995. Such forward-looking statements or information may include
financial and other projections as well as statements regarding the Company's
future plans, objectives, performance, revenues, growth, profits, operating
expenses or the Company's underlying assumptions. The words "may", "would",
"could", "will", "likely", "expect," "anticipate," "intend", "plan",
"forecast", "project", "estimate" and "believe" or other similar words and
phrases are intended to identify forward-looking statements or information.
Persons reading this press release are cautioned that such statements or
information are only predictions, and that the Company's actual future results
or performance may be materially different.
    Forward-looking statements or information in this press release include,
but are not limited to, statements or information concerning: the value and
use of data to be produced in the Phase 1 trial; the timing of announcing data
from the Phase 1 trial; the launching of a Phase 2 clinical trial in CIN
patients; the possibility of a second Phase 2 trial in HIV-positive CIN
patients; the design of the Phase 1 trial; and the collection and use of
immunological data to indicate efficacy of the compound.
    Such forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual results,
events or developments, or industry results, to be materially different from
any future results, events or developments expressed or implied by such
forward-looking statements or information. Such factors include, among others,
our need for capital, risks associated with requirements for approvals by
government agencies such as the FDA before products can be tested in clinical
trials; the possibility that such government agency approvals will not be
obtained in a timely manner or at all or will be conditioned in a manner that
would impair our ability to advance development; risks associated with the
requirement that a drug be found safe and effective after extensive clinical
trials and the possibility that the results of such trials, if commenced and
completed, will not establish the safety or efficacy of our products; our
dependence on suppliers, collaborative partners and other third parties and
the prospects and timing for negotiating supply agreements, corporate
collaborations or licensing arrangements; our ability to attract and retain
key personnel; our ability to protect and practice our intellectual property;
and other factors as described in detail in our filings with the Canadian
securities regulatory authorities at www.sedar.com. Given these risks and
uncertainties, you are cautioned not to place undue reliance on such
forward-looking statements and information, which are qualified in their
entirety by this cautionary statement.
    Assumptions underlying our expectations regarding forward-looking
statements or information contained in this press release include, among
others, that we will raise enough capital, on reasonable terms and in a timely
manner; that we will retain our key personnel; that we will obtain the
necessary regulatory approvals related to HspE7 and our adjuvant in a timely
manner; that enough HspE7 will be available to conduct our planned trials;
that we will be able to procure the necessary amount of adjuvant to conduct
our planned trials; that we will obtain timely approval from additional IRBs;
that the results from additional preclinical and clinical work, if any, will
be consistent with the results we have already obtained; that a sufficient
number of patients will be available to conduct our planned trials; and that
sufficient data will be generated to support our IND.
    In the event that any of these assumptions prove to be incorrect, or in
the event that we are impacted by any of the risks identified above, we may
not be able to continue in our business as planned.
    For a complete discussion of the assumptions, risks and uncertainties
related to our business, you are encouraged to review our filings with
Canadian securities regulatory authorities, including our 2006 Annual
Information Form filed on SEDAR at http://www.sedar.com. Historical filings
relating to the Company prior to the completion of the Company's March 23,
2006 corporate reorganization, including Old Stressgen's 2005 Annual
Information Form dated March 16, 2006 may be reviewed on SEDAR at
http://www.sedar.com under the SEDAR profile GVIC Publications Ltd.
    All forward-looking statements and information made herein are based on
our current expectations as of the date hereof and we disclaim any intention
or obligation to revise or update such forward-looking statements and
information to reflect subsequent events or circumstances, except as required
by law.

    %SEDAR: 00023483E

For further information:

For further information: Donna Slade, Director, Investor Relations, 9381
Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Dir: (858) 202-4945,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890